Prasugrel is a third generation thienopyridine antithrombotic that irreversible inhibits the ADP P2Y12 receptor, inhibiting platelet aggregation. Prasugrel is a prodrug; it undergoes rapid hydrolysis and oxidation in vivo to form its active metabolite. Clinically, prasugrel decreases the potential for ischemic events.
| Cas No. | 150322-43-3 |
|---|---|
| Purity | ≥98% |
| Formula | C20H20FNO3S |
| Formula Wt. | 373.44 |
| Chemical Name | 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate |
| IUPAC Name | [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | P6903 Info Sheet PDF |
|---|
Secco GG, Parisi R, Mirabella F, et al. P2Y12 inhibitors: pharmacologic mechanism and clinical relevance. Cardiovasc Hematol Agents Med Chem. 2013 Jun;11(2):101-5. PMID: 22963529
Hagihara K, Kazui M, Kurihara A, et al. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug Metab Dispos. 2010 Jun;38(6):898-904. PMID: 20228231.
Scott DM, Norwood RM, Parra D. P2Y12 inhibitors in cardiovascular disease: focus on prasugrel. Ann Pharmacother. 2009 Jan;43(1):64-76. PMID: 19050170.
